Sandoz, Teva Pharma plans to ramp up biosimilars production Ruchika Sharma23 Nov 2022 1:30 PM ISTTeva Chief Executive KÃ¥re Schultz said the company was targeting "80% of what's going off-patent in the next 10 years" including big sellers like the...
Allergan MD Suresh Pattathil elected as new President of OPPI Ruchika Sharma26 Sept 2022 3:00 PM ISTMumbai: The Organisation of Pharmaceutical Producers of India (OPPI), which represents the research-based pharmaceutical companies, has elected Suresh...
AbbVie receives EMA Committee positive opinion for Crohn's Disease treatment Risankizumab Ruchika Sharma21 Sept 2022 3:30 PM ISTSKYRIZI is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit.
AbbVie to pay up to USD 2.37 billion to resolve US opioid claims Ruchika Sharma31 July 2022 2:30 PM ISTNew Delhi: AbbVie Inc has agreed to pay up to $2.37 billion to resolve thousands of U.S. lawsuits against its Allergan unit over the marketing of...
Abbvie RINVOQ gets European Commission nod for treatment of Active Non-Radiographic Axial Spondyloarthritis in adults Ruchika Sharma31 July 2022 11:30 AM ISTAbbvie RINVOQ gets European Commission nod for Adults with Active Non-Radiographic Axial Spondyloarthritis
AbbVie, iSTAR Medical collaborate to develop, commercialize MINIject device for Glaucoma Ruchika Sharma21 July 2022 3:30 PM ISTUnder the terms of the agreement, iSTAR Medical will receive a $60M non-dilutive upfront payment and will continue to develop and commercialize...
AbbVie seeks EMA approval for Atogepant for prophylaxis treatment of Migraine Ruchika Sharma19 July 2022 1:45 PM ISTAtogepant is an orally administered, CGRP receptor antagonist (gepant) specifically developed for the prophylaxis treatment of migraine.
AbbVie files sNDA to USFDA for Atogepant for chronic migraine treatment Ruchika Sharma22 Jun 2022 1:30 PM ISTNorth Chicago, Ill.: AbbVie has announced that the company has submitted a supplemental New Drug Application (sNDA) for atogepant (QULIPTA) to the...
USFDA nod to AbbVie SKYRIZI for Crohn's disease treatment Ruchika Sharma18 Jun 2022 1:30 PM ISTCrohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal (or digestive) tract, causing persistent...
Aurobindo Pharma arm bags USFDA nod for Leuprolide Acetate Injection Ruchika Sharma7 Jun 2022 12:46 PM ISTLeuprolide Acetate for injection is indicated for the treatment used to treat the symptoms associated with advanced prostate cancer by way of...
Phase 3 SHINE results show postive results for IMBRUVICA (ibrutinib) in Mantle Cell Lymphoma Ruchika Sharma5 Jun 2022 3:00 PM ISTMCL is a type of aggressive, rare non-Hodgkin lymphoma (NHL) that is incurable and difficult to treat.
AbbVie, Cugene ink pact for CUG252 for treatment of autoimmune, inflammatory diseases Ruchika Sharma17 May 2022 10:00 AM ISTUnder the terms of the agreement, Cugene will receive an upfront payment of $48.5 million, and will also be eligible to receive development and...
